Stem cell technology for neurodegenerative diseases

Annals of Neurology

Volumn 70, Issue 3, 2011, Pages 353-361

  Lunn, J Simon ^a   Sakowski, Stacey A ^a   Hur, Junguk ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; SOMATOMEDIN C; SURVIVAL MOTOR NEURON PROTEIN 2; TRANSCRIPTION FACTOR SOX2; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DEPTH STIMULATION; CELL DIFFERENTIATION; CELL RENEWAL; CELL TRANSDIFFERENTIATION; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; HUNTINGTON DISEASE; MUSCULAR ATROPHY, SPINAL; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; STEM CELLS; TECHNOLOGY;

EID: 80052579667     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22487     Document Type: Article

References (81)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384-386. (Pubitemid 46184217)
2. Dobkin BH, Curt A, Guest J,. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006; 20: 5-13. (Pubitemid 43214453)
3. Wichterle H, Lieberam I, Porter JA, Jessell TM,. Directed differentiation of embryonic stem cells into motor neurons. Cell 2002; 110: 385-397.
4. Gaspard N, Vanderhaeghen P,. Mechanisms of neural specification from embryonic stem cells. Curr Opin Neurobiol 2010; 20: 37-43.
5. Yan J, Xu L, Welsh AM, et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med 2007; 4: e39.
6. Satija NK, Singh VK, Verma YK, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med 2009; 13: 4385-4402.
7. Cho GW, Noh MY, Kim HY, et al. Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev 2010; 19: 1035-1042.
8. Choi MR, Kim HY, Park JY, et al. Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010; 472: 94-98.
9. Yamanaka S,. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif 2008; 41 (suppl 1): 51-56. (Pubitemid 350295862)
10. Cho HJ, Lee CS, Kwon YW, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 2010; 116: 386-395.
11. Yakubov E, Rechavi G, Rozenblatt S, Givol D,. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophysical Research Commun 2010; 394: 189-193.
12. Judson RL, Babiarz JE, Venere M, Blelloch R,. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009; 27: 459-461.
13. Hanley J, Rastegarlari G, Nathwani AC,. An introduction to induced pluripotent stem cells. Br J Haematol 2010; 151: 16-24.
14. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-67.
15. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
16. Suzuki M, Svendsen CN,. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 2008; 31: 192-198.
17. Lunn JS, Hefferan MP, Marsala M, Feldman EL,. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors 2009; 27: 133-140.
18. Behrstock S, Ebert AD, Klein S, et al. Lesion-induced increase in survival and migration of human neural progenitor cells releasing GDNF. Cell Transplant 2008; 17: 753-762.
19. Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 2009; 106: 13594-13599.
20. Ebert AD, Barber AE, Heins BM, Svendsen CN,. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 2010; 224: 155-162.
21. Xuan AG, Long DH, Gu HG, et al. BDNF improves the effects of neural stem cells on the rat model of Alzheimer's disease with unilateral lesion of fimbria-fornix. Neurosci Lett 2008; 440: 331-335.
22. Lo B, Parham L,. Resolving ethical issues in stem cell clinical trials: the example of Parkinson disease. J Law Med Ethics 2010; 38: 257-266.
23. Brundin P, Barker RA, Parmar M,. Neural grafting in Parkinson's disease: problems and possibilities. Prog Brain Res 2010; 184: 265-294.
24. Leigh PN, Swash M, Iwasaki Y, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 84-98. (Pubitemid 39545336)
25. Reitz C, Brayne C, Mayeux R,. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7: 137-152.
26. Castellani RJ, Rolston RK, Smith MA,. Alzheimer disease. Dis Mon 2010; 56: 484-546.
27. Eckman CB, Eckman EA,. An update on the amyloid hypothesis. Neurol Clin 2007; 25: 669-682, vi. (Pubitemid 47061502)
28. Kukull WA, Bowen JD,. Dementia epidemiology. Med Clin North Am 2002; 86: 573-590. (Pubitemid 34810649)
29. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65: 664-670. (Pubitemid 30468710)
30. Bird TD, editor. Alzheimer Disease Overview. Gene Reviews. Updated 2010/03/20. Seattle (WA); University of Washington, Seatle, 1993.
31. Shruster A, Melamed E, Offen D,. Neurogenesis in the aged and neurodegenerative brain. Apoptosis 2010; 15: 1415-1421.
32. Drapeau E, Nora Abrous D,. Stem cell review series: role of neurogenesis in age-related memory disorders. Aging Cell 2008; 7: 569-589. (Pubitemid 351998617)
33. Li G, Peskind ER, Millard SP, et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 2009; 4: e5424.
34. Tuszynski MH,. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 179-189. (Pubitemid 46878982)
35. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555. (Pubitemid 40691288)
36. Damier P, Hirsch EC, Agid Y, Graybiel AM,. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122 (pt 8): 1437-1448. (Pubitemid 29374122)
37. Poewe W,. Treatments for Parkinson disease-past achievements and current clinical needs. Neurology 2009; 72: S65-S73.
38. Benabid AL, Chabardes S, Mitrofanis J, Pollak P,. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009; 8: 67-81.
39. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-1934. (Pubitemid 37409709)
40. Kim HJ,. Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons. Biochim Biophys Acta 2011; 1812: 1-11.
41. Morizane A, Darsalia V, Guloglu MO, et al. A simple method for large-scale generation of dopamine neurons from human embryonic stem cells. J Neurosci Res 2010; 88: 3467-3478.
42. Cui YF, Hargus G, Xu JC, et al. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice. Brain 2010; 133: 189-204.
43. Li M, Zhang SZ, Guo YW, et al. Human umbilical vein-derived dopaminergic-like cell transplantation with nerve growth factor ameliorates motor dysfunction in a rat model of Parkinson's disease. Neurochem Res 2010; 35: 1522-1529.
44. Cooper O, Hargus G, Deleidi M, et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci 2010; 45: 258-266.
45. Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A 2010; 107: 15921-15926.
46. Laganiere J, Kells AP, Lai JT, et al. An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci 2010; 30: 16469-16474.
47. Manfredsson FP, Okun MS, Mandel RJ,. Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 2009; 9: 375-388.
48. Xiong N, Zhang Z, Huang J, et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther 2011; 18: 394-402.
49. Falk T, Zhang S, Sherman SJ,. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Mol Neurodegener 2009; 4: 49.
50. Eberling JL, Kells AP, Pivirotto P, et al. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 2009; 20: 511-518.
51. Garbayo E, Montero-Menei CN, Ansorena E, et al. Effective GDNF brain delivery using microsphere-a promising strategy for Parkinson's disease. J Control Release 2009; 135: 119-126.
52. Emborg ME, Ebert AD, Moirano J, et al. GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys. Cell Transplant 2008; 17: 383-395. (Pubitemid 351717341)
53. Ebert AD, Beres AJ, Barber AE, Svendsen CN,. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp Neurol 2008; 209: 213-223.
54. Jourdi H, Hamo L, Oka T, et al. BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices. Neuropharmacology 2009; 56: 876-885.
55. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
56. Foroud T, Gray J, Ivashina J, Conneally PM,. Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry 1999; 66: 52-56. (Pubitemid 29101487)
57. Vonsattel JP, DiFiglia M,. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384. (Pubitemid 28237321)
58. Clelland CD, Barker RA, Watts C,. Cell therapy in Huntington disease. Neurosurg Focus 2008; 24: E9.
59. Kelly CM, Dunnett SB, Rosser AE,. Medium spiny neurons for transplantation in Huntington's disease. Biochem Soc Trans 2009; 37: 323-328.
60. Nakao N, Ogura M, Nakai K, Itakura T,. Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Neuroscience 1999; 88: 469-477. (Pubitemid 28480007)
61. Isacson O, Deacon TW, Pakzaban P, et al. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995; 1: 1189-1194.
62. Freeman TB, Cicchetti F, Bachoud-Levi AC, Dunnett SB,. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol 2011; 227: 1-9.
63. McBride JL, Behrstock SP, Chen EY, et al. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol 2004; 475: 211-219. (Pubitemid 38850019)
64. Ilieva H, Polymenidou M, Cleveland DW,. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009; 187: 761-772.
65. Yan J, Xu L, Welsh AM, et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 2006; 24: 1976-1985. (Pubitemid 44474174)
66. Xu L, Yan J, Chen D, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 2006; 82: 865-875. (Pubitemid 44564030)
67. Corti S, Locatelli F, Donadoni C, et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 2004; 127: 2518-2532. (Pubitemid 39472980)
68. Corti S, Nizzardo M, Nardini M, et al. Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum Mol Genet 2010; 19: 3782-3796.
69. Garbuzova-Davis S, Willing AE, Zigova T, et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res 2003; 12: 255-270. (Pubitemid 36736737)
70. Suzuki M, McHugh J, Tork C, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2007; 2: e689.
71. Suzuki M, McHugh J, Tork C, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008; 16: 2002-2010.
72. Lunn JS, Sakowski SA, Federici T, et al. Stem cell technology for the study and treatment of motor neuron diseases. Regen Med 2011; 6: 201-213.
73. Xu L, Ryugo DK, Pongstaporn T, et al. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol 2009; 514: 297-309.
74. Usvald D, Vodicka P, Hlucilova J, et al. Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplant 2010; 19: 1103-1122.
75. Raore B, Federici T, Taub J, et al. Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine 2011; 36: E164-E171.
76. Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16: 265-269. (Pubitemid 27280210)
77. Wee CD, Kong L, Sumner CJ,. The genetics of spinal muscular atrophies. Curr Opin Neurol 2010; 23: 450-458.
78. Corti S, Nizzardo M, Nardini M, et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 2010; 133: 465-481.
79. Corti S, Nizzardo M, Nardini M, et al. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J Clin Invest 2008; 118: 3316-3330.
80. Johe KK, Hazel TG, Muller T, et al. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 1996; 10: 3129-3140. (Pubitemid 27020541)
81. Guo X, Johe K, Molnar P, et al. Characterization of a human fetal spinal cord stem cell line, NSI-566RSC, and its induction to functional motoneurons. J Tissue Eng Regen Med 2010; 4: 181-193.